Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has received an average rating of “Buy” from the twenty-five research firms that are presently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $156.02.

A number of analysts recently issued reports on ALXN shares. Zacks Investment Research cut Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. TheStreet cut shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Friday, November 10th. Royal Bank of Canada raised their price target on shares of Alexion Pharmaceuticals to $166.00 in a research note on Tuesday, October 24th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $170.00 price target on shares of Alexion Pharmaceuticals in a research note on Monday, October 23rd. Finally, Stifel Nicolaus decreased their price target on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating for the company in a research note on Tuesday, October 24th.

Several large investors have recently added to or reduced their stakes in ALXN. Jennison Associates LLC grew its stake in shares of Alexion Pharmaceuticals by 720.0% in the third quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after buying an additional 4,682,336 shares in the last quarter. BlackRock Inc. grew its stake in shares of Alexion Pharmaceuticals by 7.0% in the second quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company’s stock valued at $2,424,428,000 after buying an additional 1,298,185 shares in the last quarter. Third Point LLC bought a new position in shares of Alexion Pharmaceuticals in the second quarter valued at $152,088,000. Janus Henderson Group PLC grew its stake in shares of Alexion Pharmaceuticals by 1,697.6% in the second quarter. Janus Henderson Group PLC now owns 1,145,918 shares of the biopharmaceutical company’s stock valued at $139,424,000 after buying an additional 1,082,171 shares in the last quarter. Finally, TIAA CREF Investment Management LLC grew its stake in shares of Alexion Pharmaceuticals by 42.2% in the second quarter. TIAA CREF Investment Management LLC now owns 3,219,961 shares of the biopharmaceutical company’s stock valued at $391,773,000 after buying an additional 955,578 shares in the last quarter. 94.33% of the stock is owned by institutional investors and hedge funds.

Shares of Alexion Pharmaceuticals (ALXN) opened at $115.76 on Friday. Alexion Pharmaceuticals has a 52 week low of $96.18 and a 52 week high of $149.34. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. The stock has a market capitalization of $25,365.93, a P/E ratio of 23.22, a P/E/G ratio of 1.23 and a beta of 1.18.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The business had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. During the same period in the prior year, the business earned $1.23 EPS. Alexion Pharmaceuticals’s revenue for the quarter was up 7.5% compared to the same quarter last year. analysts anticipate that Alexion Pharmaceuticals will post 4.82 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) Given Consensus Rating of “Buy” by Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/16/alexion-pharmaceuticals-inc-alxn-given-consensus-rating-of-buy-by-analysts.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.